Search

Your search keyword '"Gouel P"' showing total 143 results
Start Over Author "Gouel P"
143 results on '"Gouel P"'

1. The PLATO Mission

Author

Rauer, Heike, Aerts, Conny, Cabrera, Juan, Deleuil, Magali, Erikson, Anders, Gizon, Laurent, Goupil, Mariejo, Heras, Ana, Lorenzo-Alvarez, Jose, Marliani, Filippo, Martin-Garcia, Cesar, Mas-Hesse, J. Miguel, O'Rourke, Laurence, Osborn, Hugh, Pagano, Isabella, Piotto, Giampaolo, Pollacco, Don, Ragazzoni, Roberto, Ramsay, Gavin, Udry, Stéphane, Appourchaux, Thierry, Benz, Willy, Brandeker, Alexis, Güdel, Manuel, Janot-Pacheco, Eduardo, Kabath, Petr, Kjeldsen, Hans, Min, Michiel, Santos, Nuno, Smith, Alan, Suarez, Juan-Carlos, Werner, Stephanie C., Aboudan, Alessio, Abreu, Manuel, Acuña, Lorena, Adams, Moritz, Adibekyan, Vardan, Affer, Laura, Agneray, François, Agnor, Craig, Børsen-Koch, Victor Aguirre, Ahmed, Saad, Aigrain, Suzanne, Al-Bahlawan, Ashraf, Gil, M de los Angeles Alcacera, Alei, Eleonora, Alencar, Silvia, Alexander, Richard, Alfonso-Garzón, Julia, Alibert, Yann, Prieto, Carlos Allende, Almeida, Leonardo, Sobrino, Roi Alonso, Altavilla, Giuseppe, Althaus, Christian, Trujillo, Luis Alonso Alvarez, Amarsi, Anish, Eiff, Matthias Ammler-von, Amôres, Eduardo, Andrade, Laerte, Antoniadis-Karnavas, Alexandros, António, Carlos, del Moral, Beatriz Aparicio, Appolloni, Matteo, Arena, Claudio, Armstrong, David, Aliaga, Jose Aroca, Asplund, Martin, Audenaert, Jeroen, Auricchio, Natalia, Avelino, Pedro, Baeke, Ann, Baillié, Kevin, Balado, Ana, Balestra, Andrea, Ball, Warrick, Ballans, Herve, Ballot, Jerome, Barban, Caroline, Barbary, Gaële, Barbieri, Mauro, Forteza, Sebastià Barceló, Barker, Adrian, Barklem, Paul, Barnes, Sydney, Navascues, David Barrado, Barragan, Oscar, Baruteau, Clément, Basu, Sarbani, Baudin, Frederic, Baumeister, Philipp, Bayliss, Daniel, Bazot, Michael, Beck, Paul G., Bedding, Tim, Belkacem, Kevin, Bellinger, Earl, Benatti, Serena, Benomar, Othman, Bérard, Diane, Bergemann, Maria, Bergomi, Maria, Bernardo, Pierre, Biazzo, Katia, Bignamini, Andrea, Bigot, Lionel, Billot, Nicolas, Binet, Martin, Biondi, David, Biondi, Federico, Birch, Aaron C., Bitsch, Bertram, Ceballos, Paz Victoria Bluhm, Bódi, Attila, Bognár, Zsófia, Boisse, Isabelle, Bolmont, Emeline, Bonanno, Alfio, Bonavita, Mariangela, Bonfanti, Andrea, Bonfils, Xavier, Bonito, Rosaria, Bonomo, Aldo Stefano, Börner, Anko, Saikia, Sudeshna Boro, Martín, Elisa Borreguero, Borsa, Francesco, Borsato, Luca, Bossini, Diego, Bouchy, Francois, Boué, Gwenaël, Boufleur, Rodrigo, Boumier, Patrick, Bourrier, Vincent, Bowman, Dominic M., Bozzo, Enrico, Bradley, Louisa, Bray, John, Bressan, Alessandro, Breton, Sylvain, Brienza, Daniele, Brito, Ana, Brogi, Matteo, Brown, Beverly, Brown, David, Brun, Allan Sacha, Bruno, Giovanni, Bruns, Michael, Buchhave, Lars A., Bugnet, Lisa, Buldgen, Gaël, Burgess, Patrick, Busatta, Andrea, Busso, Giorgia, Buzasi, Derek, Caballero, José A., Cabral, Alexandre, Calderone, Flavia, Cameron, Robert, Cameron, Andrew, Campante, Tiago, Martins, Bruno Leonardo Canto, Cara, Christophe, Carone, Ludmila, Carrasco, Josep Manel, Casagrande, Luca, Casewell, Sarah L., Cassisi, Santi, Castellani, Marco, Castro, Matthieu, Catala, Claude, Fernández, Irene Catalán, Catelan, Márcio, Cegla, Heather, Cerruti, Chiara, Cessa, Virginie, Chadid, Merieme, Chaplin, William, Charpinet, Stephane, Chiappini, Cristina, Chiarucci, Simone, Chiavassa, Andrea, Chinellato, Simonetta, Chirulli, Giovanni, Christensen-Dalsgaard, Jorgen, Church, Ross, Claret, Antonio, Clarke, Cathie, Claudi, Riccardo, Clermont, Lionel, Coelho, Hugo, Coelho, Joao, Cogato, Fabrizio, Colomé, Josep, Condamin, Mathieu, Conseil, Simon, Corbard, Thierry, Correia, Alexandre C. M., Corsaro, Enrico, Cosentino, Rosario, Costes, Jean, Cottinelli, Andrea, Covone, Giovanni, Creevey, Orlagh L., Crida, Aurelien, Csizmadia, Szilard, Cunha, Margarida, Curry, Patrick, da Costa, Jefferson, da Silva, Francys, Dalal, Shweta, Damasso, Mario, Damiani, Cilia, Damiani, Francesco, Chagas, Maria Liduina das, Davies, Melvyn, Davies, Guy, Davies, Ben, Davison, Gary, de Almeida, Leandro, de Angeli, Francesca, de Barros, Susana Cristina Cabral, Leão, Izan de Castro, de Freitas, Daniel Brito, de Freitas, Marcia Cristina, De Martino, Domitilla, de Medeiros, José Renan, de Paula, Luiz Alberto, de Plaa, Jelle, De Ridder, Joris, Deal, Morgan, Decin, Leen, Deeg, Hans, Degl'Innocenti, Scilla, Deheuvels, Sebastien, del Burgo, Carlos, Del Sordo, Fabio, Delgado-Mena, Elisa, Demangeon, Olivier, Denk, Tilmann, Derekas, Aliz, Desidera, Silvano, Dexet, Marc, Di Criscienzo, Marcella, Di Giorgio, Anna Maria, Di Mauro, Maria Pia, Rial, Federico Jose Diaz, Díaz-García, José-Javier, Dima, Marco, Dinuzzi, Giacomo, Dionatos, Odysseas, Distefano, Elisa, Nascimento Jr., Jose-Dias do, Domingo, Albert, D'Orazi, Valentina, Dorn, Caroline, Doyle, Lauren, Duarte, Elena, Ducellier, Florent, Dumaye, Luc, Dumusque, Xavier, Dupret, Marc-Antoine, Eggenberger, Patrick, Ehrenreich, David, Eigmüller, Philipp, Eising, Johannes, Emilio, Marcelo, Eriksson, Kjell, Ermocida, Marco, Giribaldi, Riano Isidoro Escate, Eschen, Yoshi, Estrela, Inês, Evans, Dafydd Wyn, Fabbian, Damian, Fabrizio, Michele, Faria, João Pedro, Farina, Maria, Farinato, Jacopo, Feliz, Dax, Feltzing, Sofia, Fenouillet, Thomas, Ferrari, Lorenza, Ferraz-Mello, Sylvio, Fialho, Fabio, Fienga, Agnes, Figueira, Pedro, Fiori, Laura, Flaccomio, Ettore, Focardi, Mauro, Foley, Steve, Fontignie, Jean, Ford, Dominic, Fornazier, Karin, Forveille, Thierry, Fossati, Luca, Franca, Rodrigo de Marca, da Silva, Lucas Franco, Frasca, Antonio, Fridlund, Malcolm, Furlan, Marco, Gabler, Sarah-Maria, Gaido, Marco, Gallagher, Andrew, Galli, Emanuele, Garcia, Rafael A., Hernández, Antonio García, Munoz, Antonio Garcia, García-Vázquez, Hugo, Haba, Rafael Garrido, Gaulme, Patrick, Gauthier, Nicolas, Gehan, Charlotte, Gent, Matthew, Georgieva, Iskra, Ghigo, Mauro, Giana, Edoardo, Gill, Samuel, Girardi, Leo, Winter, Silvia Giuliatti, Giusi, Giovanni, da Silva, João Gomes, Zazo, Luis Jorge Gómez, Gomez-Lopez, Juan Manuel, Hernández, Jonay Isai González, Murillo, Kevin Gonzalez, Gorius, Nicolas, Gouel, Pierre-Vincent, Goulty, Duncan, Granata, Valentina, Grenfell, John Lee, Grießbach, Denis, Grolleau, Emmanuel, Grouffal, Salomé, Grziwa, Sascha, Guarcello, Mario Giuseppe, Gueguen, Loïc, Guenther, Eike Wolf, Guilhem, Terrasa, Guillerot, Lucas, Guiot, Pierre, Guterman, Pascal, Gutiérrez, Antonio, Gutiérrez-Canales, Fernando, Hagelberg, Janis, Haldemann, Jonas, Hall, Cassandra, Handberg, Rasmus, Harrison, Ian, Harrison, Diana L., Hasiba, Johann, Haswell, Carole A., Hatalova, Petra, Hatzes, Artie, Haywood, Raphaelle, Hébrard, Guillaume, Heckes, Frank, Heiter, Ulrike, Hekker, Saskia, Heller, René, Helling, Christiane, Helminiak, Krzysztof, Hemsley, Simon, Heng, Kevin, Hermans, Aline, Hermes, JJ, Torres, Nadia Hidalgo, Hinkel, Natalie, Hobbs, David, Hodgkin, Simon, Hofmann, Karl, Hojjatpanah, Saeed, Houdek, Günter, Huber, Daniel, Huesler, Joseph, Hui-Bon-Hoa, Alain, Huygen, Rik, Huynh, Duc-Dat, Iro, Nicolas, Irwin, Jonathan, Irwin, Mike, Izidoro, André, Jacquinod, Sophie, Jannsen, Nicholas Emborg, Janson, Markus, Jeszenszky, Harald, Jiang, Chen, Mancebo, Antonio José Jimenez, Jofre, Paula, Johansen, Anders, Johnston, Cole, Jones, Geraint, Kallinger, Thomas, Kálmán, Szilárd, Kanitz, Thomas, Karjalainen, Marie, Karjalainen, Raine, Karoff, Christoffer, Kawaler, Steven, Kawata, Daisuke, Keereman, Arnoud, Keiderling, David, Kennedy, Tom, Kenworthy, Matthew, Kerschbaum, Franz, Kidger, Mark, Kiefer, Flavien, Kintziger, Christian, Kislyakova, Kristina, Kiss, László, Klagyivik, Peter, Klahr, Hubert, Klevas, Jonas, Kochukhov, Oleg, Köhler, Ulrich, Kolb, Ulrich, Koncz, Alexander, Korth, Judith, Kostogryz, Nadiia, Kovács, Gábor, Kovács, József, Kozhura, Oleg, Krivova, Natalie, Kučinskas, Arunas, Kuhlemann, Ilyas, Kupka, Friedrich, Laauwen, Wouter, Labiano, Alvaro, Lagarde, Nadege, Laget, Philippe, Laky, Gunter, Lam, Kristine Wai Fun, Lambrechts, Michiel, Lammer, Helmut, Lanza, Antonino Francesco, Lanzafame, Alessandro, Martiz, Mariel Lares, Laskar, Jacques, Latter, Henrik, Lavanant, Tony, Lawrenson, Alastair, Lazzoni, Cecilia, Lebre, Agnes, Lebreton, Yveline, Etangs, Alain Lecavelier des, Leinhardt, Zoe, Leleu, Adrien, Lendl, Monika, Leto, Giuseppe, Levillain, Yves, Libert, Anne-Sophie, Lichtenberg, Tim, Ligi, Roxanne, Lignieres, Francois, Lillo-Box, Jorge, Linsky, Jeffrey, Liu, John Scige, Loidolt, Dominik, Longval, Yuying, Lopes, Ilídio, Lorenzani, Andrea, Ludwig, Hans-Guenter, Lund, Mikkel, Lundkvist, Mia Sloth, Luri, Xavier, Maceroni, Carla, Madden, Sean, Madhusudhan, Nikku, Maggio, Antonio, Magliano, Christian, Magrin, Demetrio, Mahy, Laurent, Maibaum, Olaf, Malac-Allain, LeeRoy, Malapert, Jean-Christophe, Malavolta, Luca, Maldonado, Jesus, Mamonova, Elena, Manchon, Louis, Mann, Andrew, Mantovan, Giacomo, Marafatto, Luca, Marconi, Marcella, Mardling, Rosemary, Marigo, Paola, Marinoni, Silvia, Marques, Érico, Marques, Joao Pedro, Marrese, Paola Maria, Marshall, Douglas, Perales, Silvia Martínez, Mary, David, Marzari, Francesco, Masana, Eduard, Mascher, Andrina, Mathis, Stéphane, Mathur, Savita, Figueiredo, Ana Carolina Mattiuci, Maxted, Pierre F. L., Mazeh, Tsevi, Mazevet, Stephane, Mazzei, Francesco, McCormac, James, McMillan, Paul, Menou, Lucas, Merle, Thibault, Meru, Farzana, Mesa, Dino, Messina, Sergio, Mészáros, Szabolcs, Meunier, Nadége, Meunier, Jean-Charles, Micela, Giuseppina, Michaelis, Harald, Michel, Eric, Michielsen, Mathias, Michtchenko, Tatiana, Miglio, Andrea, Miguel, Yamila, Milligan, David, Mirouh, Giovanni, Mitchell, Morgan, Moedas, Nuno, Molendini, Francesca, Molnár, László, Mombarg, Joey, Montalban, Josefina, Montalto, Marco, Monteiro, Mário J. P. F. G., Morales, Juan Carlos, Morales-Calderon, Maria, Morbidelli, Alessandro, Mordasini, Christoph, Moreau, Chrystel, Morel, Thierry, Morello, Guiseppe, Morin, Julien, Mortier, Annelies, Mosser, Benoît, Mourard, Denis, Mousis, Olivier, Moutou, Claire, Mowlavi, Nami, Moya, Andrés, Muehlmann, Prisca, Muirhead, Philip, Munari, Matteo, Musella, Ilaria, Mustill, Alexander James, Nardetto, Nicolas, Nardiello, Domenico, Narita, Norio, Nascimbeni, Valerio, Nash, Anna, Neiner, Coralie, Nelson, Richard P., Nettelmann, Nadine, Nicolini, Gianalfredo, Nielsen, Martin, Niemi, Sami-Matias, Noack, Lena, Noels-Grotsch, Arlette, Noll, Anthony, Norazman, Azib, Norton, Andrew J., Nsamba, Benard, Ofir, Aviv, Ogilvie, Gordon, Olander, Terese, Olivetto, Christian, Olofsson, Göran, Ong, Joel, Ortolani, Sergio, Oshagh, Mahmoudreza, Ottacher, Harald, Ottensamer, Roland, Ouazzani, Rhita-Maria, Paardekooper, Sijme-Jan, Pace, Emanuele, Pajas, Miriam, Palacios, Ana, Palandri, Gaelle, Palle, Enric, Paproth, Carsten, Parro, Vanderlei, Parviainen, Hannu, Granado, Javier Pascual, Passegger, Vera Maria, Pastor-Morales, Carmen, Pätzold, Martin, Pedersen, May Gade, Hidalgo, David Pena, Pepe, Francesco, Pereira, Filipe, Persson, Carina M., Pertenais, Martin, Peter, Gisbert, Petit, Antoine C., Petit, Pascal, Pezzuto, Stefano, Pichierri, Gabriele, Pietrinferni, Adriano, Pinheiro, Fernando, Pinsonneault, Marc, Plachy, Emese, Plasson, Philippe, Plez, Bertrand, Poppenhaeger, Katja, Poretti, Ennio, Portaluri, Elisa, Portell, Jordi, de Mello, Gustavo Frederico Porto, Poyatos, Julien, Pozuelos, Francisco J., Moroni, Pier Giorgio Prada, Pricopi, Dumitru, Prisinzano, Loredana, Quade, Matthias, Quirrenbach160, ndreas, Reina6, Julio Arturo Rabanal, Soares, Maria Cristina Rabello, Raimondo, Gabriella, Rainer, Monica, Rodón, Jose Ramón, Ramón-Ballesta, Alejandro, Zapata, Gonzalo Ramos, Rätz, Stefanie, Rauterberg, Christoph, Redman, Bob, Redmer, Ronald, Reese, Daniel, Regibo, Sara, Reiners, Ansgar, Reinhold, Timo, Renie, Christian, Ribas, Ignasi, Ribeiro, Sergio, Ricciardi, Thiago Pereira, Rice, Ken, Richard, Olivier, Riello, Marco, Rieutord, Michel, Ripepi, Vincenzo, Rixon, Guy, Rockstein, Steve, Rodríguez, María Teresa Rodrigo, Díaz, Luisa Fernanda Rodríguez, Garcia, Juan Pablo Rodriguez, Rodriguez-Gomez, Julio, Roehlly, Yannick, Roig, Fernando, Rojas-Ayala, Bárbara, Rolf, Tobias, Rørsted, Jakob Lysgaard, Rosado, Hugo, Rosotti, Giovanni, Roth, Olivier, Roth, Markus, Rousseau, Alex, Roxburgh, Ian, Roy, Fabrice, Royer, Pierre, Ruane, Kirk, Mastropasqua, Sergio Rufini, de Galarreta, Claudia Ruiz, Russi, Andrea, Saar, Steven, Saillenfest, Melaine, Salaris, Maurizio, Salmon, Sebastien, Saltas, Ippocratis, Samadi, Réza, Samadi, Aunia, Samra, Dominic, da Silva, Tiago Sanches, Carrasco, Miguel Andrés Sánchez, Santerne, Alexandre, Santoli, Francesco, Santos, Ângela R. G., Mesa, Rosario Sanz, Sarro, Luis Manuel, Scandariato, Gaetano, Schäfer, Martin, Schlafly, Edward, Schmider, François-Xavier, Schneider, Jean, Schou, Jesper, Schunker, Hannah, Schwarzkopf, Gabriel Jörg, Serenelli, Aldo, Seynaeve, Dries, Shan, Yutong, Shapiro, Alexander, Shipman, Russel, Sicilia, Daniela, Sanmartin, Maria Angeles Sierra, Sigot, Axelle, Silliman, Kyle, Silvotti, Roberto, Simon, Attila E., Napoli, Ricardo Simoyama, Skarka, Marek, Smalley, Barry, Smiljanic, Rodolfo, Smit, Samuel, Smith, Alexis, Smith, Leigh, Snellen, Ignas, Sódor, Ádám, Sohl, Frank, Solanki, Sami K., Sortino, Francesca, Sousa, Sérgio, Southworth, John, Souto, Diogo, Sozzetti, Alessandro, Stamatellos, Dimitris, Stassun, Keivan, Steller, Manfred, Stello, Dennis, Stelzer, Beate, Stiebeler, Ulrike, Stokholm, Amalie, Storelvmo, Trude, Strassmeier, Klaus, Strøm, Paul Anthony, Strugarek, Antoine, Sulis, Sophia, Švanda, Michal, Szabados, László, Szabó, Róbert, Szabó, Gyula M., Szuszkiewicz, Ewa, Talens, Geert Jan, Teti, Daniele, Theisen, Tom, Thévenin, Frédéric, Thoul, Anne, Tiphene, Didier, Titz-Weider, Ruth, Tkachenko, Andrew, Tomecki, Daniel, Tonfat, Jorge, Tosi, Nicola, Trampedach, Regner, Traven, Gregor, Triaud, Amaury, Trønnes, Reidar, Tsantaki, Maria, Tschentscher, Matthias, Turin, Arnaud, Tvaruzka, Adam, Ulmer, Bernd, Ulmer-Moll, Solène, Ulusoy, Ceren, Umbriaco, Gabriele, Valencia, Diana, Valentini, Marica, Valio, Adriana, Guijarro, Ángel Luis Valverde, Van Eylen, Vincent, Van Grootel, Valerie, van Kempen, Tim A., Van Reeth, Timothy, Van Zelst, Iris, Vandenbussche, Bart, Vasiliou, Konstantinos, Vasilyev, Valeriy, de Mascarenhas, David Vaz, Vazan, Allona, Nunez, Marina Vela, Velloso, Eduardo Nunes, Ventura, Rita, Ventura, Paolo, Venturini, Julia, Trallero, Isabel Vera, Veras, Dimitri, Verdugo, Eva, Verma, Kuldeep, Vibert, Didier, Martinez, Tobias Vicanek, Vida, Krisztián, Vigan, Arthur, Villacorta, Antonio, Villaver, Eva, Aparicio, Marcos Villaverde, Viotto, Valentina, Vorobyov, Eduard, Vorontsov, Sergey, Wagner, Frank W., Walloschek, Thomas, Walton, Nicholas, Walton, Dave, Wang, Haiyang, Waters, Rens, Watson, Christopher, Wedemeyer, Sven, Weeks, Angharad, Weingril, Jörg, Weiss, Annita, Wendler, Belinda, West, Richard, Westerdorff, Karsten, Westphal, Pierre-Amaury, Wheatley, Peter, White, Tim, Whittaker, Amadou, Wickhusen, Kai, Wilson, Thomas, Windsor, James, Winter, Othon, Winther, Mark Lykke, Winton, Alistair, Witteck, Ulrike, Witzke, Veronika, Woitke, Peter, Wolter, David, Wuchterl, Günther, Wyatt, Mark, Yang, Dan, Yu, Jie, Sanchez, Ricardo Zanmar, Osorio, María Rosa Zapatero, Zechmeister, Mathias, Zhou, Yixiao, Ziemke, Claas, and Zwintz, Konstanze

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - Earth and Planetary Astrophysics, Astrophysics - Solar and Stellar Astrophysics
Abstract

PLATO (PLAnetary Transits and Oscillations of stars) is ESA's M3 mission designed to detect and characterise extrasolar planets and perform asteroseismic monitoring of a large number of stars. PLATO will detect small planets (down to <2 R_(Earth)) around bright stars (<11 mag), including terrestrial planets in the habitable zone of solar-like stars. With the complement of radial velocity observations from the ground, planets will be characterised for their radius, mass, and age with high accuracy (5 %, 10 %, 10 % for an Earth-Sun combination respectively). PLATO will provide us with a large-scale catalogue of well-characterised small planets up to intermediate orbital periods, relevant for a meaningful comparison to planet formation theories and to better understand planet evolution. It will make possible comparative exoplanetology to place our Solar System planets in a broader context. In parallel, PLATO will study (host) stars using asteroseismology, allowing us to determine the stellar properties with high accuracy, substantially enhancing our knowledge of stellar structure and evolution. The payload instrument consists of 26 cameras with 12cm aperture each. For at least four years, the mission will perform high-precision photometric measurements. Here we review the science objectives, present PLATO's target samples and fields, provide an overview of expected core science performance as well as a description of the instrument and the mission profile at the beginning of the serial production of the flight cameras. PLATO is scheduled for a launch date end 2026. This overview therefore provides a summary of the mission to the community in preparation of the upcoming operational phases.

Published
2024

2. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Author

Sébastien Thureau, Bernard Dubray, Romain Modzelewski, Pierre Bohn, Sébastien Hapdey, Sabine Vincent, Elodie Anger, David Gensanne, Nicolas Pirault, Gouel Pierrick, and Pierre Vera

Subjects
Positron emission tomography, 18fluoro-deoxy-D-glucose, 18fluoro-misonidasole, Lung cancer, Hypoxia, Radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on 18FDG and 18F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy. Method Twenty-one NSCLC patients, selected from a prospective phase II trial, had 18FDG- and 18F-miso PET/CT before the start of radiotherapy and 18FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment 18FDG hotspot (70% of SUVmax) (plan 2), pre-treatment 18F-miso target (SUVmax > 1.4) (plan 3) and per-treatment 18FDG residual (40% of SUVmax). (plan 4). Results The mean target volumes were 4.8 cc (± 1.1) for 18FDG hotspot, 38.9 cc (± 14.5) for 18F-miso and 36.0 cc (± 10.1) for per-treatment 18FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for 18FDG hotspot, 18F-miso and per-treatment 18FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in 18FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in 18F-miso and per-treatment 18FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to 18F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for 18FDG hotspot and per-treatment 18FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to 18FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for 18FDG hotspot and 18F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios. Conclusion Escalated doses can be selectively planned in NSCLC target volumes delineated on 18FDG and 18F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials. Trial registration (RTEP5, NCT01576796, registered 15 june 2012)

Published
2018
Full Text
View/download PDF

3. Interest Rate Dynamics and Commodity Prices

Author

Gouel, Christophe, Ma, Qingyin, and Stachurski, John

Subjects
Economics - Theoretical Economics, Mathematics - Numerical Analysis, Mathematics - Optimization and Control
Abstract

In economic studies and popular media, interest rates are routinely cited as a major factor behind commodity price fluctuations. At the same time, the transmission channels are far from transparent, leading to long-running debates on the sign and magnitude of interest rate effects. Purely empirical studies struggle to address these issues because of the complex interactions between interest rates, prices, supply changes, and aggregate demand. To move this debate to a solid footing, we extend the competitive storage model to include stochastically evolving interest rates. We establish general conditions for existence and uniqueness of solutions and provide a systematic theoretical and quantitative analysis of the interactions between interest rates and prices., Comment: 48 pages, 6 figures

Published
2023

4. Corrélations entre la composition des mélanges d'hydrocarbures et leurs propriétés physiques Correlations Betweenthe Composition of Hydrocarbon Mixtures and Their Physical Properties.

Author

Gouel P.

Subjects
Chemical technology, TP1-1185, Energy industries. Energy policy. Fuel trade, HD9502-9502.5
Abstract

L'optimisation de l'exploitation des gisements d'hydrocarbures est devenue aujourd'hui,avec la grave crise énergétique que nous traversons, le problème numéro un du mondepétrolier. Afin d'améliorer la production on est obligé de mettre en ceuvre des techniques derécupération assistée qui coûtent très cher et dont le choix est basé sur les propriétés physiques du pétrole, de la roche réservoir et l'état d'exploitation même du gisement.Nous avons donc étudié le comportement volumétrique et viscosimétrique de la fraction lourde d'hydrocarbures ainsi que la mise au point d'une technique d'analyse de cette fraction. Nos mesures ont porté essentiellement sur les corps purs suivants : nCe, nC, nC, nC9, nClo, nC12, nC14, nCls, cyclo Ce, cyclo C" cyclo Cs, méthyl cyclo Cg, benzène, toluène, xylène et triméthylbenzène dans un domaine de température et de pression s'étendant de 20 à 120 °C et de la pression atmosphérique à 400 bars.A partir de ces données expérimentales nous avons développé deux modèles prévisionnels : l'un pour la masse volumique des mélanges basé sur l'équation d'état de Redlich-Kwong et l'introduction de coefficients d'interaction binaire, l'autre sur les viscosités des mélanges à partir d'une équation d'Andrade modi-fiée et de la loi de mélange d'Arrhénius. The principal problem facing the petroleum industry during the present severe energy crisis is ta optimise production from hydrocarbon fields. In order to improve production, enhanced recovery techniques must be used. These are extremely expensive and are chosen on the basis of physical properties of the ail, the réservoir rocks and working conditions of the field. The volumetric and viscometric behovior of the heavy hydrocarbon fraction was therefore studied. A technique for analyzing this fraction was also developed. M~asurements essentially concerned the following pure substances : nC, nC, nC, nC, nC1e,nC,,, nC14,nC18, cyclo C,,cycloC,, cyclo Ce, methyl cycIo Cs, benzène, toluene, xylene and trimethylbenzene in temoerature and pressure range from 20 ta 120' C and from on aimospheric pressure to 440 bars. of state and the introduction of binary interaction coefficients, and the other concerned the viscosities of the mixtures on the basis of a modified Andrade equation and the Arrhenius mixing rule.

Published
2006
Full Text
View/download PDF

5. Longitudinal Study of an IP Geolocation Database

Author

Gouel, Matthieu, Vermeulen, Kevin, Fourmaux, Olivier, Friedman, Timur, and Beverly, Robert

Subjects
Computer Science - Networking and Internet Architecture
Abstract

IP geolocation - the process of mapping network identifiers to physical locations - has myriad applications. We examine a large collection of snapshots from a popular geolocation database and take a first look at its longitudinal properties. We define metrics of IP geo-persistence, prevalence, coverage, and movement, and analyse 10 years of geolocation data at different location granularities. Across different classes of IP addresses, we find that significant location differences can exist even between successive instances of the database - a previously underappreciated source of potential error when using geolocation data: 47% of end users IP addresses move by more than 40 km in 2019. To assess the sensitivity of research results to the instance of the geo database, we reproduce prior research that depended on geolocation lookups. In this case study, which analyses geolocation database performance on routers, we demonstrate impact of these temporal effects: median distance from ground truth shifted from 167 km to 40 km when using a two months apart snapshot. Based on our findings, we make recommendations for best practices when using geolocation databases in order to best encourage reproducibility and sound measurement., Comment: Technical Report related to a paper appeared in Network Traffic Measurement and Analysis Conference (TMA 2021)

Published
2021

6. Circulating microbiome analysis in patients with perioperative anaphylaxis

Author

Luc de Chaisemartin, Dragos Ciocan, Aurélie Gouel-Chéron, Vanessa Granger, Dan Longrois, Philippe Montravers, Anne-Marie Cassard, and Sylvie Chollet-Martin

Subjects
IgE-mediated hypersensitivity, microbiome, neuromuscular blocking agents, perioperative anaphylaxis, tryptase, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundPerioperative anaphylaxis is a rare and acute systemic manifestation of drug-induced hypersensitivity reactions that occurs following anesthesia induction; the two main classes of drugs responsible for these reactions being neuromuscular blocking agents (NMBA) and antibiotics. The sensitization mechanisms to the drugs are not precisely known, and few risk factors have been described. A growing body of evidence underlines a link between occurrence of allergy and microbiota composition. However, no data exist on microbiota in perioperative anaphylaxis. The aim of this study was to compare circulating microbiota richness and composition between perioperative anaphylaxis patients and matched controls.MethodsCirculating 16s rDNA was quantified and sequenced in serum samples from 20 individuals with fully characterized IgE-mediated NMBA-related anaphylaxis and 20 controls matched on sex, age, NMBA received, type of surgery and infectious status. Microbiota composition was analyzed with a published bioinformatic pipeline and links with patients clinical and biological data investigated.ResultsAnalysis of microbiota diversity showed that anaphylaxis patients seem to have a richer circulating microbiota than controls, but no major differences of composition could be detected with global diversity indexes. Pairwise comparison showed a difference in relative abundance between patients and controls for Saprospiraceae, Enterobacteriaceae, Veillonellaceae, Escherichia-Shigella, Pseudarcicella, Rhodoferax, and Lewinella. Some taxa were associated with concentrations of mast cell tryptase and specific IgE.ConclusionWe did not find a global difference in terms of microbiota composition between anaphylaxis patient and controls. However, several taxa were associated with anaphylaxis patients and with their biological data. These findings must be further confirmed in different settings to broaden our understanding of drug anaphylaxis pathophysiology and identify predisposition markers.

Published
2024
Full Text
View/download PDF

7. Alias Resolution Based on ICMP Rate Limiting

Author

Vermeulen, Kevin, Ljuma, Burim, Addanki, Vamsi, Gouel, Matthieu, Fourmaux, Olivier, Friedman, Timur, and Rejaie, Reza

Subjects
Computer Science - Networking and Internet Architecture
Abstract

Alias resolution techniques (e.g., Midar) associate, mostly through active measurement, a set of IP addresses as belonging to a common router. These techniques rely on distinct router features that can serve as a signature. Their applicability is affected by router support of the features and the robustness of the signature. This paper presents a new alias resolution tool called Limited Ltd. that exploits ICMP rate limiting, a feature that is increasingly supported by modern routers that has not previously been used for alias resolution. It sends ICMP probes toward target interfaces in order to trigger rate limiting, extracting features from the probe reply loss traces. It uses a machine learning classifier to designate pairs of interfaces as aliases. We describe the details of the algorithm used by Limited Ltd. and illustrate its feasibility and accuracy. Limited Ltd. not only is the first tool that can perform alias resolution on IPv6 routers that do not generate monotonically increasing fragmentation IDs (e.g., Juniper routers) but it also complements the state-of-the-art techniques for IPv4 alias resolution. All of our code and the collected dataset are publicly available., Comment: Preprint to appear in Proceedings of Passive and Active Measurement (PAM 2020) Conference, Eugene, OR, March 2020

Published
2020

11. Impact of the Bayesian penalized likelihood algorithm (Q.Clear®) in comparison with the OSEM reconstruction on low contrast PET hypoxic images

Author

Edgar Texte, Pierrick Gouel, Sébastien Thureau, Justine Lequesne, Bertrand Barres, Agathe Edet-Sanson, Pierre Decazes, Pierre Vera, and Sébastien Hapdey

Subjects
PET/CT, Hypoxia, NSCLC, BPL reconstruction, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Abstract Purpose To determine the impact of the Bayesian penalized likelihood (BPL) reconstruction algorithm in comparison to OSEM on hypoxia PET/CT images of NSCLC using 18F-MIZO and 18F-FAZA. Materials and methods Images of low-contrasted (SBR = 3) micro-spheres of Jaszczak phantom were acquired. Twenty patients with lung neoplasia were included. Each patient benefitted from 18F-MISO and/or 18F-FAZA PET/CT exams, reconstructed with OSEM and BPL. Lesion was considered as hypoxic if the lesion SUVmax > 1.4. A blind evaluation of lesion detectability and image quality was performed on a set of 78 randomized BPL and OSEM images by 10 nuclear physicians. SUVmax, SUVmean, and hypoxic volumes using 3 thresholding approaches were measured and compared for each reconstruction. Results The phantom and patient datasets showed a significant increase of quantitative parameters using BPL compared to OSEM but had no impact on detectability. The optimal beta parameter determined by the phantom analysis was β350. Regarding patient data, there was no clear trend of image quality improvement using BPL. There was no correlation between SUVmax increase with BPL and either SUV or hypoxic volume from the initial OSEM reconstruction. Hypoxic volume obtained by a SUV > 1.4 thresholding was not impacted by the BPL reconstruction parameter. Conclusion BPL allows a significant increase in quantitative parameters and contrast without significantly improving the lesion detectability or image quality. The variation in hypoxic volume by BPL depends on the method used but SUV > 1.4 thresholding seems to be the more robust method, not impacted by the reconstruction method (BPL or OSEM). Trial registration ClinicalTrials.gov , NCT02490696 . Registered 1 June 2015

Published
2020
Full Text
View/download PDF

15. A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement

Author

Elyse Colard, Sarkis Delcourt, Laetitia Padovani, Sébastien Thureau, Arthur Dumouchel, Pierrick Gouel, Justine Lequesne, Bardia Farman Ara, Pierre Vera, David Taïeb, Isabelle Gardin, Dominique Barbolosi, and Sébastien Hapdey

Subjects
Dynamic PET, Parametric imaging, FDG kinetics, Lung cancer, Quantification, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Abstract Background In FDG-PET, SUV images are hampered by large potential biases. Our aim was to develop an alternative method (ParaPET) to generate 3D kinetic parametric FDG-PET images easy to perform in clinical oncology. Methods The key points of our method are the use of a new error model of PET measurement extracted from a late dynamic PET acquisition of 15 min, centered over the lesion and an image-derived input function (IDIF). The 15-min acquisition is reconstructed to obtain five images of FDG mean activity concentration and images of its variance to model errors of PET measurement. Our approach is carried out on each voxel to derive 3D kinetic parameter images. ParaPET was evaluated and compared to Patlak analysis as a reference. Hunter and Barbolosi methods (Barbolosi-Bl: with blood samples or Barbolosi-Im: with IDIF) were also investigated and compared to Patlak. Our evaluation was carried on K i index, the net influx rate and its maximum value in the lesion (K i,max). Results This parameter was obtained from 41 non-small cell lung cancer lesions associated with 4 to 5 blood samples per patient, required for the Patlak analysis. Compare to Patlak, the median relative difference and associated range (median; [min;max]) in K i,max estimates were not statistically significant (Wilcoxon test) for ParaPET (− 3.0%; [− 31.9%; 47.3%]; p = 0.08) but statistically significant for Barbolosi-Bl (− 8.0%; [− 30.8%; 53.7%]; p = 0.001), Barbolosi-Im (− 7.9%; [− 38.4%; 30.6%]; p = 0.007) or Hunter (32.8%; [− 14.6%; 132.2%]; p

Published
2018
Full Text
View/download PDF

17. Place de l’analgésie péridurale dans la chirurgie de l’aorte à ciel ouvert en France : étude multicentrique AP2A

Author

Soulé, Christelle, Moussa, Mouhamed, Leviel, Florent, Le Gac, Grégoire, Daccache, Gérard, Le Moal, Charlène, Parigi, Claire, Gouel, Aurélie, Montandrau, Olivier, Joffredo, Jean-Baptiste, Todorova, Violeta, Guerci, Philippe, de Mollien, Louis, Siaudeau, Hélène, Orion, François, Lesvier, Benoit, Mongardon, Nicolas, Maurel, Blandine, Rozec, Bertrand, Brisard, Laurent, and Cinotti, Raphaël

Abstract

Malgré des bénéfices potentiels, l’utilisation de l’analgésie péridurale (APD) dans la chirurgie aortique abdominale à ciel ouvert est inconnue en France.

Published
2024
Full Text
View/download PDF

19. Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates

Author

Flore Gouel, Anne-Sophie Rolland, Jean-Christophe Devedjian, Thierry Burnouf, and David Devos

Subjects
Amyotrophic lateral sclerosis, growth factors, therapeutic, stem cell, human platelet lysate, Neurology. Diseases of the nervous system, RC346-429
Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system—e.g., development, plasticity, maintenance, neurogenesis—neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.

Published
2019
Full Text
View/download PDF

22. Comment choisir la question de son essai clinique ? Les conseils du Réseau Recherche de la SFAR

Author

Sigaut, Stéphanie, Rolle, Amélie, Evain, Jean-Noël, Léger, Maxime, Bezu, Lucillia, Mazeraud, Aurélien, Gouel, Aurélie, Boussemart, Pierre, Jacquens, Alice, Lang, Elodie, Bouras, Marwan, Yavchitz, Amélie, Le Guen, Morgan, Kerever, Sébastien, Meuret, Ludovic, Daoui, Chafia, Beloeil, Hélène, and Cinotti, Raphaël

Abstract

Tous les travaux de recherche commencent par une question. Cette question doit être claire et bien définie dès le départ, car sa nature influencera toutes les étapes suivantes, notamment la méthodologie. Il s’agit donc d’une étape majeure dans la réalisation d’un projet de recherche, qui demande de l’expertise et du travail. Une bonne question émerge en effet de l’expérience clinique et des recherches réalisées antérieurement. Elle nécessite pour être pertinente une maîtrise de la littérature existante sur le sujet, une ouverture à de nouvelles idées, de nouvelles techniques, de nouvelles méthodologies, de l’imagination et de la créativité, mais aussi une grande attention aux conseils de ses mentors et des experts établis. Cette question doit répondre à des critères de faisabilité, d’intérêt, de nouveauté, d’éthique et de pertinence (les critères FINER). Elle doit être formulée de manière structurée pour assurer un maximum de clarté, en suivant par exemple le cadre PICOT (pour population, intervention étudiée, contrôle, outcomeet timeframe). Choisir et formuler la question principale de son essai clinique n’est donc pas un exercice purement sémantique.

Published
2023
Full Text
View/download PDF

32. Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models

Author

Dejoux, Alice, Zhu, Qianqian, Ganneau, Christelle, Goff, Odile Richard-Le, Godon, Ophélie, Lemaitre, Julien, Relouzat, Francis, Huetz, François, Sokal, Aurélien, Vandenberghe, Alexis, Pecalvel, Cyprien, Hunault, Lise, Derenne, Thomas, Gillis, Caitlin M., Iannascoli, Bruno, Wang, Yidan, Rose, Thierry, Mertens, Christel, Nicaise-Roland, Pascale, England, Patrick, Mahévas, Matthieu, de Chaisemartin, Luc, Le Grand, Roger, Letscher, Hélène, Saul, Frederick, Pissis, Cédric, Haouz, Ahmed, Reber, Laurent L., Chappert, Pascal, Jönsson, Friederike, Ebo, Didier G., Millot, Gaël A., Bay, Sylvie, Chollet-Martin, Sylvie, Gouel-Chéron, Aurélie, and Bruhns, Pierre

Abstract

Neuromuscular blocking agents (NMBAs) relax skeletal muscles to facilitate surgeries and ease intubation but can lead to adverse reactions, including complications because of postoperative residual neuromuscular blockade (rNMB) and, in rare cases, anaphylaxis. Both adverse reactions vary between types of NMBAs, with rocuronium, a widely used nondepolarizing NMBA, inducing one of the longest rNMB durations and highest anaphylaxis incidences. rNMB induced by rocuronium can be reversed by the synthetic γ-cyclodextrin sugammadex. However, in rare cases, sugammadex can provoke anaphylaxis. Thus, additional therapeutic options are needed. Rocuronium-induced anaphylaxis is proposed to rely on preexisting rocuronium-binding antibodies. To understand the pathogenesis of rocuronium-induced anaphylaxis and to identify potential therapeutics, we investigated the memory B cell antibody repertoire of patients with suspected hypersensitivity to rocuronium. We identified polyclonal antibody repertoires with a high diversity among V(D)J genes without evidence of clonal groups. When recombinantly expressed, these antibodies demonstrated specificity and low affinity for rocuronium without cross-reactivity for other NMBAs. Moreover, when these antibodies were expressed as human immunoglobulin E (IgE), they triggered human mast cell activation and passive systemic anaphylaxis in transgenic mice, although their affinities were insufficient to serve as reversal agents. Rocuronium-specific, high-affinity antibodies were thus isolated from rocuronium-immunized mice. The highest-affinity antibody was able to reverse rocuronium-induced neuromuscular blockade in nonhuman primates with kinetics comparable to that of sugammadex. Together, these data support the hypothesis that antibodies cause anaphylactic reactions to rocuronium and pave the way for improved diagnostics and neuromuscular blockade reversal agents.

Published
2024
Full Text
View/download PDF

33. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma.

Author

Aurélie Gouel-Chéron, Bernard Allaouchiche, Caroline Guignant, Fanny Davin, Bernard Floccard, Guillaume Monneret, and AzuRea Group

Subjects
Medicine, Science
Abstract

OBJECTIVE: Major trauma is characterized by a pro-inflammatory response, followed by an immunosuppression. Recently, in trauma patients, the lack of recovery of monocyte Human Leukocyte Antigen DR (mHLA-DR, a biomarker of ICU-acquired immunosuppression) between days 1-2 and days 3-4 has been demonstrated to be independently associated with sepsis development. The main objective of this study was to determine whether early measurements of IL-6 (interleukin-6) and IL-10 plasma concentrations (as markers of initial severity) could improve, in association with mHLA-DR recovery, the prediction of sepsis occurrence in severe trauma patients. DESIGN: Prospective observational study over 24 months in a Trauma ICU at university hospital. PATIENTS: Trauma patients with an ISS over 25 and age over 18 were included. MEASUREMENTS AND MAIN RESULTS: mHLA-DR was assessed by flow cytometry, IL-6 and IL-10 concentrations by ELISA. 100 consecutive severely injured patients were monitored (mean ISS 37±10). 37 patients developed sepsis. IL-6 concentrations and slope of mHLA-DR expression between days 1-2 and days 3-4 were significantly different between septic and non-septic patients. IL-10 was not detectable in most patients. After adjustment for usual clinical confounders, when assessed as a pair, multivariate logistic regression analysis revealed that a slope of mHLA-DR expression (days 3-4/days 1-2)≤1.1 and a IL-6 concentration ≥ 67.1 pg/ml remained highly associated with the development of sepsis (adjusted OR 18.4, 95% CI 4.9; 69.4, p = .00002). CONCLUSIONS: After multivariate regression logistic analysis, when assessed as a pair, a high IL-6 concentration and a persistent mHLA-DR decreased expression were found to be in relation with the development of sepsis with the best predictive value. This study underlines the usefulness of daily monitoring of immune function to identify trauma patients at a high risk of infection.

Published
2012
Full Text
View/download PDF

42. KIT A ROULER© : un enjeu de société !

Author

Arino, Aude and Gouel, Catherine

Abstract

Afin de prévenir le risque routier qui reste la 1recause de mortalité au travail et priorité nationale et régionale (PNST et PRST 4) le service de santé au travail, EnSanté accompagne ses entreprises adhérentes dans l’évaluation de ce risque et la sensibilisation de leurs salariés. Dans une volonté de mettre fin à une approche théorique de la prévention et de la rendre accessible à tous, EnSanté a créé un jeu KIT A ROULER© un Enjeu de Société ! qui permet de diversifier et dynamiser les sensibilisations collectives en entreprise.

Published
2024
Full Text
View/download PDF

45. 24 PET/CT-MR guided radiation therapy workflow

Author

Gensanne, D., primary, Gouel, P., additional, Decaze, P., additional, Edet-Sanson, A., additional, Callonnec, F., additional, Douvrin, F., additional, Benyoucef, A., additional, Dubray, B., additional, Gardin, I., additional, and Vera, P., additional

Published
2018
Full Text
View/download PDF

46. Advanced telehealth technology improves home-based exercise therapy for people with stable chronic obstructive pulmonary disease: a systematic review.

Author

Bonnevie, Tristan, Smondack, Pauline, Elkins, Mark, Gouel, Benoit, Medrinal, Clément, Combret, Yann, Muir, Jean-François, Cuvelier, Antoine, Prieur, Guillaume, and Gravier, Francis-Edouard

Subjects
OBSTRUCTIVE lung disease treatment, QUADRICEPS muscle physiology, ANXIETY, MENTAL depression, DYSPNEA, EXERCISE therapy, HEALTH status indicators, HOME care services, HOSPITAL care, INFORMATION storage & retrieval systems, MEDICAL databases, MEDLINE, META-analysis, HEALTH outcome assessment, PHYSICAL therapy, QUALITY of life, SELF-efficacy, TELEMEDICINE, SYSTEMATIC reviews, RESEARCH bias, PUBLICATION bias, PHYSICAL activity, ADVERSE health care events, EXERCISE tolerance
Abstract

How effective is home-based exercise therapy delivered using advanced telehealth technology (ATT-ET) for people with chronic obstructive pulmonary disease (COPD) compared with: no exercise therapy (ET), in/outpatient ET, and home-based ET without ATT? Systematic review and meta-analysis of randomised trials. People with stable COPD referred for ET. ATT-ET. Exercise capacity, quality of life, functional dyspnoea, cost-effectiveness and various secondary outcomes. Fifteen eligible trials involved 1,522 participants. Compared with no ET, ATT-ET improved exercise capacity (four studies, 6-minute walk test MD 15 m, 95% CI 5 to 24) and probably improved quality of life (four studies, SMD 0.22, 95% CI 0.00 to 0.43) and functional dyspnoea (two studies, Chronic Respiratory Questionnaire-Dyspnoea MD 2, 95% CI 0 to 4). ATT-ET had a similar effect as in/outpatient ET on functional dyspnoea (two studies, SMD –0.05, 95% CI –0.39 to 0.29) and a similar or better effect on quality of life (two studies, SMD 0.23, 95% CI –0.04 to 0.50) but its relative effect on exercise capacity was very uncertain (three studies, 6-minute walk test MD 6 m, 95% CI –26 to 37). ATT-ET had a similar effect as home-based ET without ATT on exercise capacity (three studies, 6-minute walk test MD 2 m, 95% CI –16 to 19) and similar or better effects on quality of life (three studies, SMD 0.79, 95% CI –0.04 to 1.62) and functional dyspnoea (two studies, Chronic Respiratory Questionnaire-Dyspnoea MD 2, 95% CI 0 to 4). ATT-ET had effects on most secondary outcomes that were similar to or better than each comparator. ATT-ET improves exercise capacity, functional dyspnoea and quality of life compared with no ET, although some benefits may be small. Its benefits are generally similar to in/outpatient ET and similar to or better than home-based ET without ATT. PROSPERO CRD42020165773. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Evaluation dosimétrique d’une augmentation de doses de radiothérapie au volume fonctionnel défini par TEP FMISO ou FDG dans les cancers bronchiques non à petites cellules

Author

Thureau, S., Gensanne, D., pirault, n., Modzelewski, R., anger, e, Vincent, S, Hapdey, S., Bohn, P., Dubray, B., Vera, P., Gouel, P., Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), service de radiothérapie et de physique médicale, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service de médecine nucléaire [Rouen], and CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel)

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

48. ParaPET, a new statistical approach to derive 3D maps of FDG-PET kinetic parameters

Author

Colard, E, Padovani, L, Delcourt, S, Thureau, S, Farman-Ara, B, Gouel, P, Gardin, I, Vera, P, Taïeb, D, Barbolosi, D, Hapdey, S, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service de Radiothérapie, APHM, Hôpital de la Timone, Marseille, Hôpital de la Timone [CHU - APHM] (TIMONE), Département de radiothérapie et de physique médicale, and Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel)

Subjects
[SDV]Life Sciences [q-bio], [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

49. Variabilité multicentrique de l’estimée du volume tumoral métabolique total en TEP au FDG dans le cadre du PHRC multicentrique RTEP7

Author

Buvat, I, nioche, c, DUPONT, A, Thureau, S, Modzelewski, R, Gouel, P, Massabeau, C, Giraud, P, Vera, Pierre, Hapdey, S, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Service de médecine nucléaire [Rouen], and CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

50. ParaPET, a new methodology to derive parametric PET images of FDG kinetics based on an mathematical approach integrating an error model of measurements

Author

Colard, E, Delcourt, S, Padovani, L, Thureau, S, Farman-Ara, B, Gouel, P, Gardin, I, Vera, P, Taïeb, D, Barbolosi, D, Hapdey, S, Service de Radiothérapie, APHM, Hôpital de la Timone, Marseille, Hôpital de la Timone [CHU - APHM] (TIMONE), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Département de radiothérapie et de physique médicale, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service de médecine nucléaire [Rouen], and CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel)

Subjects
[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results